All In Biotech

NDA 017453 · Teva Branded Pharm

Proglycem

Diazoxide · Oral

Priority review

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1976

May 28, 1976

Approved uses

1

Original approval plus efficacy supplements

Registered trials

34

7 Phase 3, 3 recruiting

FAERS reports

737

643 serious, 98 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 6, 2026.

INDICATIONS AND USAGE PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 28, 1976 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • PROGLYCEM · DIAZOXIDE 50MG/ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Diazoxide" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective134
  • hypoglycaemia101
  • off label use73
  • hyperglycaemia46
  • drug ineffective for unapproved indication38
  • drug interaction30
  • product use in unapproved indication29
  • oedema peripheral25
  • malignant neoplasm progression23
  • nausea23
  • death22
  • insulinoma22

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
20059
20066
200712
20088
20098
201012
201113
201216
201332
201431
201556
201631
201730
201831
201945
202029
202155
202252
202364
202463
202596
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Proglycem (Diazoxide)

2024 spending

$166K

Beneficiaries

18

49 claims

Per beneficiary

$9,197

$12.77 per unit

View as table
YearSpending
2020$2,182,624
2021$549,245
2022$254,833
2023$205,884
2024$165,551

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 115 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.